PT  - JOURNAL ARTICLE
ED  - ,
TI  - Duovent – is logic enough?
AID  - 10.1136/dtb.23.1.3
DP  - 1985 Jan 14
TA  - Drug and Therapeutics Bulletin
PG  - 3--4
VI  - 23
IP  - 1
4099  - http://dtb.bmj.com/content/23/1/3.short
4100  - http://dtb.bmj.com/content/23/1/3.full
SO  - Drug Ther Bull1985 Jan 14; 23
AB  - Duovent (WB Pharmaceuticals) is a fixed-dose combination aerosol containing fenoterol (100 μg per puff) - a β2-adrenoceptor stimulant, and ipratropium (40 μg per puff) - an atropine-like agent. It is marketed for the treatment of bronchoconstriction in patients with asthma, chronic bronchitis or emphysema. The manufacturer claims that it is a ‘logical combination’ offering ‘first line treatment’, but the British National Formulary1 states that compound bronchodilators (including Duovent) ‘have no place in the management of patients with airways obstruction’.